Stockreport

Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market [Seeking Alpha]

Zevra Therapeutics, Inc.  (ZVRA) 
PDF ZVRA's valuation appears deeply discounted, with significant upside from EU expansion, pipeline assets Celiprolol and KP-1077, and a strong $200M cash position. FY26 [Read more]